Results 111 to 120 of about 97,803,787 (197)

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2575-2584, 15 November 2026.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang   +9 more
wiley   +1 more source

Further Insights Into the Mechanisms of Lymph Node Metastasis

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Metastasis of malignant tumors arising from epithelial organs to sentinel lymph nodes has important implications for prognosis, staging, and therapeutic decision‐making. Recent insights into anatomic pathways, pathogenesis, molecular interactions, and genetic factors have encouraged scientists and clinicians to develop drugs that target ...
S. David Nathanson   +5 more
wiley   +1 more source

1,2,4-Triazole-Tethered Indolinones as New Cancer-Fighting Small Molecules Targeting VEGFR-2: Synthesis, Biological Evaluations and Molecular Docking

open access: yesPharmaceuticals
Targeting the VEGFR-2 signaling pathway is an inveterate approach toward combating pancreatic and hepatocellular cancers. Based on Sunitinib, the FDA-approved VEGFR-2 inhibitor, novel indolin-2-one-triazole hybrids were designed and synthesized as anti ...
Ahmed E. Elsawi   +5 more
doaj   +1 more source

The Efferocytosis‐Driven Macrophage Polarization: A Concerto in the Tumor Immunosuppressive Microenvironment

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Efferocytosis is a key process for macrophages to clear apoptotic cells, which undergoes the “ Find Me” chemotaxis signal stage, the “eat me” phagocytosis recognition stage and the “digest me” digestion stage in turn. During the aforementioned three stages, various signaling molecules released by apoptotic cells can promote the phenotypic polarization ...
Qiuping Chen   +3 more
wiley   +1 more source

Neointimal Hyperplasia and Restenosis: Epidemiology, Pathophysiology, Animal Models, Clinical Features, Diagnosis, and Management

open access: yesMedComm, Volume 7, Issue 11, November 2026.
The overall graphical diagram to summarize the pathological characteristics, pathogenesis, clinical manifestation, preclinical animal models, diagnostic methods, and intervention strategies for neointimal hyperplasia. Neointimal hyperplasia results from excessive proliferation and intimal migration of vascular smooth muscle cells (VSMCs) in the ...
Kaixu Wang   +6 more
wiley   +1 more source

Exosomes in Cancer: The Biology, Function, Diagnosis, and Therapy

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Tumor‐derived exosomes and nonmembranous extracellular nanoparticles (exomeres/supermeres) constitute a heterogeneous communication network that drives cancer progression. By shuttling functional biomolecules across tissue‐specific barriers, these nanoparticles orchestrate local microenvironmental remodeling, immune suppression, premetastatic niche ...
Jun Wu   +8 more
wiley   +1 more source

Gastric Cancer: Epidemiology, Risk Factors, Pathogenesis, Clinical Features, Diagnosis, and Management

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This comprehensive review summarizes gastric cancer epidemiology, multifactorial risk factors (like infectious, dietary, genetic), pathogenesis such as precancerous evolution, molecular alterations, and a focus on the bidirectional interactions between gastric cancer cells and macrophages in the tumor microenvironment.
Yixuan Xin   +6 more
wiley   +1 more source

Efficacy and Safety of Lucitanib in Advanced Thymic Carcinoma: A Randomized Phase II Trial

open access: yesMedComm, Volume 7, Issue 11, November 2026.
In this randomized phase II trial, 68 patients with advanced thymic carcinoma after chemotherapy received lucitanib (n = 46) or placebo (n = 22). Median PFS was 5.8 versus 3.7 months by IRC (HR: 0.60; p = 0.105) and 6.6 versus 1.9 months by investigators (HR: 0.53; p = 0.031). Hypertension was the most common grade 3 TRAE (50%).
Wentao Fang   +21 more
wiley   +1 more source

Liver Injury Repair and Regeneration: Molecular Mechanisms and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 11, November 2026.
This review outlines the spatiotemporal framework of liver injury repair and regeneration, orchestrated by molecular signaling, multicellular niche crosstalk, metabolic reprogramming, and interorgan communication. Post‑injury regenerative cascades (initiation, proliferation, termination) rely on crosstalk between hepatocytes, Kupffer cells, hepatic ...
Mingyue Pan   +15 more
wiley   +1 more source

Target‐Engagement Prediction From Molecular Structure, In Vitro and Animal Data: A Tutorial for Early Assessment of Clinical Drug Exposure and Therapeutic/Adverse Potential Using the ANDROMEDA and PLATO Software on the InSilicoTrials Platform

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT The target‐engagement predictor, implemented within the InSilicoTrials cloud‐based, AI‐powered platform for model‐informed drug discovery and development, enables early exploration of time‐dependent pharmacological responses. Predictions can be generated using inputs ranging from molecular structure to in vitro, animal, and clinical data ...
Niccolò Totis   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy